Zafrens specializes in difficult modalities and targets, prosecuted through an internal pipeline as well as through collaborative partnerships. Our proprietary Z-Screen technology replaces the conventional 96-well plate experimental format with a 50,000-well plate format containing a built-in mRNA sequencer. This allows every cell that is imaged in an assay to be sequenced, as well, revealing rich causal relationships between perturbations, molecular responses, cell function and cell interactions.

At JPM 2026 we are proud to announce our three new divisions:

Zafrens Biologics: Function-fist discovery of biologics and cell therapies

Zafrens Cellmods: Small-molecule modulators of transcription factors and epigenetic states

Zafrens AI: Predictive models on drug safety, selectivity and MoA built on the worlds largest database of Drug-seq and cell-painting data (500,000 novel compounds)